CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 105 participants.

Also called NCT05356403

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 105 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05356403
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Australia, Brazil, Bulgaria, Germany, Hungary, Italy, Mexico, Poland, Romania, South Korea, Spain (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT05356403. Randomized; double masking; primary purpose treatment. Start 2022-08-26 (actual); primary completion 2024-02-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
Condition
Chronic Kidney Diseases
Condition
Pruritus
Intervention (Drug)
Difelikefalin 1 mg Oral Tablet
Intervention (Drug)
Placebo Oral Tablet
Lead sponsor
Cara Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct05356403
Content hash
283dd4487ea096f3742e7a7ef5553aeefab0897f2f15ffa1c42ccac27414f82d